Alnylam: DMC recommends continuation of APOLLO Phase 3 trial
Alnylam Pharmaceuticals announced that the Data Monitoring Committee, or DMC, for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy met on October 7, 2016 and recommended continuation of the trial without modification. The APOLLO DMC met at the request of the company following the decision - announced on October 5, 2016 - to discontinue development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. The DMC will continue to meet periodically per their remit to monitor the overall safety of patisiran in the APOLLO study through its completion. The APOLLO study has completed enrollment of 225 patients at 44 sites in 19 countries, between December 2013 and January 2016.